uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Safety and efficacy of the combination of pegylated interferon-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
St Olavs Hosp, Dept Hematol, PB 8250 Sluppen, NO-7006 Trondheim, Norway.;Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, Trondheim, Norway..
Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark..
Skane Univ Hosp, Dept Hematol & Vasc Disorders, Lund, Sweden..
Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland.;Helsinki Univ Hosp, Ctr Comprehens Canc, Dept Hematol, Helsinki, Sweden..
Show others and affiliations
2016 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 30, no 9, 1853-1860 p.Article in journal (Refereed) Published
Abstract [en]

Dasatinib (DAS) and interferon-a have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-alpha 2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 mu g/week and it increased to 25 mu g/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR4 was achieved by 46% and MR4.5 by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS +/- PegIFN is warranted.

Place, publisher, year, edition, pages
2016. Vol. 30, no 9, 1853-1860 p.
National Category
Cancer and Oncology Hematology
URN: urn:nbn:se:uu:diva-305498DOI: 10.1038/leu.2016.121ISI: 000383786400003PubMedID: 27133821OAI: oai:DiVA.org:uu-305498DiVA: diva2:1038497
Available from: 2016-10-18 Created: 2016-10-18 Last updated: 2016-10-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Höglund, MartinPersson, IngerOlsson-Strömberg, Ulla
By organisation
HaematologyDepartment of Statistics
In the same journal
Cancer and OncologyHematology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 191 hits
ReferencesLink to record
Permanent link

Direct link